Monday 19 October 2026
Export MOTS’s income statement to Excel — free account
Motus GI Holdings, Inc.
MOTS Healthcare Medical Devices
Motus GI Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $319,000.00, down 46.1% from fiscal 2022. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow MOTS
| Older periods | Jun '23 | Sep '23 | Dec '23 | Mar '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
9.11 | 12.57 | 3.30 | 11.59 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.97) | (2.33) | (0.57) | (1.87) | |
P/B ratio |
0.00 | 0.00 | 0.39 | 1.24 | |
Price to Tangible BV |
0.00 | 0.00 | 0.39 | 1.24 | |
EV/Sales |
11.43 | 22.09 | (5.12) | 3.51 | |
EV/EBITDA |
0.00 | 0.00 | 0.15 | 0.00 | |
EV/Operating CF |
(0.42) | (0.60) | 0.15 | (0.14) | |
EV/FCF |
(0.42) | (0.60) | 0.14 | (0.13) | |
Quick Ratio |
1.94 | 1.29 | 1.54 | 1.52 | |
Current Ratio |
2.20 | 1.49 | 1.76 | 1.74 | |
Net Debt/EBITDA |
(0.52) | (1.60) | 1.20 | 1.43 | |
Debt/Assets |
83.57% | 108.20% | 31.46% | 32.56% | |
Debt/Equity |
(10.19) | (3.71) | 0.85 | 0.75 | |
Asset Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF/Net income |
0.86 | 0.73 | 0.66 | 0.27 | |
Capex/Depreciation |
(0.22) | (0.07) | 0.00 | 0.00 | |
Interest Coverage |
(10.90) | (10.78) | (45.78) | (25.32) | |
Research and Development Expense of Revenue |
671.68% | 805.81% | 876.56% | 710.94% | |
Selling, General and Administrative Expense of Revenue |
1,747.79% | 2,022.09% | 2,639.06% | 2,535.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
43.36% | 108.14% | 167.19% | 110.94% | |
Graham Net Nets |
(0.57) | (0.92) | 1.16 | 0.46 | |
Graham Number |
49.49 | 56.56 | 0.00 | 0.00 | |
Earnings Yield |
(566.88%) | (491.30%) | (2,196.15%) | (3,553.86%) | |
Free Cash Flow Yield |
(301.90%) | (294.77%) | (1,072.93%) | (224.79%) | |
Revenue per Share |
0.22 | 0.14 | 0.08 | 0.01 | |
Operating CF per Share |
(5.10) | (3.14) | (2.29) | (0.23) | |
Capex per Share |
(0.10) | (0.03) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(5.20) | (3.16) | (2.29) | (0.23) | |
Cash per Share |
16.91 | 9.14 | 6.12 | 0.57 | |
Shareholders Equity per Share |
(1.91) | (3.96) | 3.32 | 0.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.91) | (3.96) | 3.32 | 0.36 | |
Free Cash Flow |
(2.62) | (1.98) | (1.86) | (2.02) | |
Working Capital |
5.36 | 2.21 | 2.49 | 2.44 | |
Capital Expenditures |
(0.05) | (0.02) | 0.00 | — | |
Net Current Asset Value |
(2.89) | (4.23) | 1.22 | 1.75 | |
EV/EBIT |
0.00 | 0.00 | 0.14 | 0.00 | |
Capex to Sales |
0.43 | 0.19 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.09 | 0.13 | 0.07 | 0.07 | |
Average Payables |
1.84 | 2.08 | 1.91 | 1.48 | |
Average Inventory |
0.74 | 0.71 | 0.37 | 0.35 | |
Average Assets |
15.91 | 12.93 | 12.44 | 9.65 | |
Average Common Equity |
1.50 | (0.86) | 2.83 | 0.99 |
Columns are period end dates